Greater Than Minimal Risk, No Direct Benefit - Bridging Drug Trials and Novel Therapy in Pediatric Populations

Am J Bioeth. 2020 May;20(4):102-103. doi: 10.1080/15265161.2020.1730488.
No abstract available

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Anemia, Sickle Cell / prevention & control*
  • Benzylamines
  • Child
  • Clinical Trials as Topic*
  • Cyclams
  • Ethics Committees, Research*
  • Heterocyclic Compounds / therapeutic use*
  • Humans
  • Minors
  • Research Design*
  • Risk Assessment

Substances

  • Benzylamines
  • Cyclams
  • Heterocyclic Compounds
  • plerixafor